Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 22,752

Document Document Title
WO/2017/036992A1
The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions,such as a medicament, dietary supplement, functio...  
WO/2017/038991A1
Provided are a composition for muscle building and a method for building muscle. The present invention pertains to a composition for muscle building, said composition comprising citrulline or a salt thereof and a branched amino acid or a...  
WO/2017/035659A1
In one aspect, the Invention relates to methods and compositions to remove replicate genetic material, such as duplicate copy number variations (CNVs) present in genetic material using targeted endonuclease technology with one guide, suc...  
WO/2017/038945A1
Provided is a therapeutic agent for diseases associated with the accumulation of abnormal substances in cells which contains, as an active ingredient, a substance for suppressing the expression of ERdj8, or a substance for suppressing an...  
WO/2017/037567A1
This invention relates to a method of treating a condition or a disease associated with decreased levels or activity of frataxin, including Friedreich's ataxia, comprising administering to a subject in needthereof a therapeutically effec...  
WO/2017/037717A1
Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are p...  
WO/2017/036993A1
The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional foo...  
WO/2017/033963A1
The present invention addresses the problem of providing a substance that has an effect of increasing ATP in cells, in particular, an ATP increasing agent that has an effect much stronger than the increasing effect achieved by using inos...  
WO/2017/027967A1
The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or ass...  
WO/2017/031502A1
The present invention relates to methods for conferring mTOR mediated physiological benefits by administering a composition having phospholipids, omega-3 fatty acids, and an antioxidant, or a krill extract to a mammal in need thereof.  
WO/2017/026429A1
The present invention pertains to a muscle synthesis promoting agent which exhibits muscle synthesis promotion effects in a level equal to or higher than whey protein but with a lesser ingestion (administration) amount than whey protein....  
WO/2017/026516A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. The present invention provides a compound having Nrf2 activation ability.  
WO/2017/014120A1
Provided are a composition for stimulating TRPV1, a use for the composition for stimulating TRPV1, and a method for stimulating TRPV1. It was discovered that a specific cyclic dipeptide or a salt thereof has a TRPV1 stimulation effect. T...  
WO/2017/013031A1
The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5- hydroxytryptamine B1 receptor-stimulating agent, an...  
WO2017009491A1
A natural glucose transport promoting peptide comprising a glucose transport promoting fragment of a protein selected from SEQUENCE ID NO's: 1 to 6, and a composition comprising a plurality of glucose transport promoting peptides, is des...  
WO/2017/010382A1
The present invention provides an agent for the treatment of myotonic dystrophy having as an active ingredient at least one compound selected from the group consisting of erythromycin, clarithromycin, and azithromycin, a pharmacologicall...  
WO2017009644A1
An inhibitor of a receptor tyrosine kinase, in particular selected from a compound of formula (I), (II) or (III) as defined in the specification for use in the treatment of fascioscapulohumeral dystrophy (FSHD)wherein formula (I) is exem...  
WO/2017/009487A1
A topical, cosmetic or pharmaceutical, composition comprising a cosmetically or pharmaceutically effective amount of a peptide comprising an amino acid sequence of SEQUENCE ID NO.1 or a variant thereof.  
WO2017009472A1
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (nota...  
WO/2017/004966A1
The present invention relates to a new pyrazine derivative, and preparation method and medical application thereof. The pyrazine derivative can remove a free radical, suppress calcium overload, has an effect of protecting cells, and is u...  
WO/2017/004142A1
Provided herein are methods and compositions for the treatment of myopathies.  
WO/2017/000869A1
The present invention falls within the technical field of medicines. In particular, the present invention relates to a thiazideamide derivative compound, a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition...  
WO/2016/207354A1
The present invention relates to a FGF19 polypeptide for its use as an agent increasing muscle fibers size, in the prevention and/or treatment of muscle atrophy in a mammal body.  
WO/2016/208695A1
Disclosed is a means that can be used for modifying a biologically or pharmacologically active substance from a form incapable of permeating the blood-brain barrier to a form capable of permeating the blood-brain barrier. Also disclosed ...  
WO/2016/203404A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/203405A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/204230A1
A stem cell administration method includes an administration step for injecting a stem cell-containing solution containing stem cells collected from an animal (donor animal) or subcultured stem cells obtained by subculturing the stem cel...  
WO/2016/203406A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/202341A1
The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention furth...  
WO/2016/199878A1
Provided is a sigma-receptor binding agent that is characterized by containing an alkyl ether derivative represented by general formula [1] or a salt thereof. (In the formula, R1 and R2 are the same or different and indicate a hydrogen a...  
WO/2016/197980A1
The present invention relates to the technical field of pharmaceutical chemistry, especially to Baicalin crystal form A, and preparation method and application thereof. The crystal form shows characteristic peaks at X-ray powder diffract...  
WO/2016/197945A1
The present invention relates to the use of a composition for preparing a medicament for the treatment of amyotrophic lateral sclerosis and associated disorders. The composition comprises 3-methyl-1-phenyl-2-pyrazoline-5-one or pharmaceu...  
WO/2016/192657A1
The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisom...  
WO/2016/196350A1
The present invention relates to compositions (e.g., AUFl encoding compositions) for muscle cell uptake, satellite cell populations and compositions containing muscle satellite cell populations, pharmaceutical compositions, methods of pr...  
WO/2016/195074A1
A read-through therapeutic containing a lincomycin compound as an active ingredient.  
WO/2016/195493A1
Title: Means and methods for treating facioscapulohumeral muscular dystrophy (FSHD). The invention is related to facioscapulohumeral muscular dystrophy (FSHD) and in particular therapeutic means and methods for the treatment of the disea...  
WO/2016/190774A1
Point changes to the 3'UTR nucleotide sequence of the VEGF gene which significantly increase the lifespan of the mRNA transcription product of said gene in mammalian cells have been identified. A gene construct with an optimal list of th...  
WO/2016/187682A1
The present invention relates to a composition based on a mixture of standardised extracts or essential oils of Pterodon pubescens Benth. and Cordia verbenacea DC. Also disclosed are the use thereof and formulations comprising said compo...  
WO/2016/186772A3
Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non- naturally occurring Clustered Regularly Interspaced Short Palindro...  
WO/2016/186772A2
Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non- naturally occurring Clustered Regularly Interspaced Short Palindro...  
WO/2016/184832A1
The present invention provides compounds of formula (I) wherein A, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the comp...  
WO/2016/181394A1
The present invention discloses a composition comprising cannabis natural extract, or synthetic cannabinoids, for use in treating a subject suffering from fibromyalgia. The present invention further discloses methods and uses of the afor...  
WO/2016/175136A1
The present invention addresses the problem of providing: a novel composition for suppressing muscular fatty change, which contains a component that can be ingested safely for a long period; and others. It is found that quercetin or a gl...  
WO/2016/169028A1
The present invention provides three novel conotoxin peptides, namely κ-CPTx-btl06, κ-CPTx-btl07 and κ-CPTx-btl08, amino acid sequences thereof being shown as SEQ ID NO: 1, 2 and 3 respectively. The present invention also relates to p...  
WO/2016/172224A1
An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding ...  
WO/2016/171249A1
Provided is the compound represented by formula (I) (in the formula, Y1 is O or the like; Z1 is, C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently hydrogen atoms or the like; R1 is a s...  
WO/2016/170353A1
(3S)-Tetrahydrofuran-3-yl(4S)-4-isopropyl-1,4,6,7-tetrahydro -5H-imidazo[4,5-c]-pyridine-5-carboxylate, and salts thereof for use in the treatment of pain.  
WO/2016/166480A1
The invention relates to a derivative of general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and/or pre...  
WO/2016/164089A3
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/...  
WO/2016/163912A1
The invention relates to medicine, and more particularly to neurosurgery and trauma surgery, and can be used for stimulating nerve regeneration through the use of a gene therapeutic construct which codes for vascular endothelial growth f...  

Matches 101 - 150 out of 22,752